Tick tock.

This is not a big deal. They will not be delisted.

PH3 Topline presentation tomorrow...
The study met its primary endpoint and demonstrated that as a primary therapeutic intervention a single vaginal dose of DARE-BV1 achieved clinical cure rates of 70-81%.

Won’t hit $.40.

That’s waaaaay under cash on hand

Love it. Trading like early January.
Pop up coming

Multiple PH3, multiple PH2, multiple early stages Trials. Huge grants coming in. The most recent was 70% of the current market cap. 40M shares and a
$70M market cap.
It currently sits at historic support.

I believe an announcement Is due.
$73M cash, PH3, multiple early stage trials, and the marketing rights to a German COVID PILL.
At the support level when it bounced to $3.23.

On January 21 this year the stock closed at 0.77
On January 25, 0.66
On January 27, the stock closed at 0.75
On 1 February 0.70
On February 2, which is the day the company first announced the development of the vaccine, the stock closed at $ 1
On February 4, 1.08
But the big rise in nothing occurred on February 8 to a price of 3.34
On February 9 it fell to 2.2
On February 10 the stock closed at 1.91 and the continuation is known to this day ... the stock continued down and back to the prices of the end of January before the announcement regarding the vaccine and some announcements related to the rest of the platform.
Now pay attention. Last week’s price ranged from 0.66 to 0.76 with a close on Friday at 0.71

I don’t know how one cannot have a position in AEZS right now. The people of Europe are being locked down again. They do not trust the rushed shots. But AEZS_inc has marketing rights and is helping a Covid pill that is very attractive to this market.
Trades cash value.

Support is there.

Waaay undervalued.

Insanity here

Broke through.

Recon already has contracts with CNPC…. CNPC just discovered the largest reserve ever in China….! https://www.naturalgasintel.com/huge-oil-natural-gas-discovery-reported-in-chinas-tarim-basin-2/

A break of $3.50 and it gives us the next leg up.

Looks like a reversal is a good possibility here.

Double bottom.
$55M raised at mid $6s.
Trading at cash on hand value.
Multiple diversified contracts coming in

Any sources of news on the patent trial anyone can send me to?

Lowest volume since 6/10 and right at the bottom resistance.

$71M cash.
$91M market cap.
Tiny float.
Raise in the mid $6s.
Seems undervalued.
Blockchain, energy, and energy services.

It’s crazy they didn’t cover.

We will get BLA news soon, then journal, the the cherry on top would be leaps human trials.

Yes 1.1Mish shares converted.
Still 21% of the float short… and institutions added it looks like.

New numbers showing 34% institutional ownership.

New short numbers…
8.62M shares or 21%+ of the float…
Hardly ANY SHORTS COVERED.

What’s this thing worth with minolock
Approval? And I believe they will get approval.

I expect an update on a pre BLA fda meeting well before that

So what it looks like is State street owned something like 3.8% before. They sold the news…. Dumping 1.8M shares into the bid. Then bought back even more.

State Street bought over 5% of the company on this dip with an average cost of $13

Morning gap closed.
900k shares borrowed to short this morning.

Broke $9.60.
Gaps will start closing as we move forward. Reversal.

Ameritrade just went no margin trading on CVM?!

Strong open could see $10 today.

Then gaps start closing.

You are incorrect

Imagine an BLA announcement followed by human trial announcement for LEAPS….

Also John Cipriano ; Sr. VP of Regulatory Affairs for $CVM (Cel-Sci) and former Deputy Director of the FDA

“In fact, we’re not the "only ones" who believe in our data, we have been contacted, the company has been contacted by a "number of experts" in the field and even one "regulatory expert".....who believes our phase three data is "very compelling" and the application should be accepted and the product will be ultimately approved.”

John Cipriano – Sr. VP of Regulatory Affairs for CVM (Cel-Sci) and a former Deputy Director of the FDA….
“I would like to let you know that I have already contacted FDA, both the Division of Oncology Products, which is the group that will manage any application that comes forward, and the Division of Orphan Drug Products. Our product is an orphan drug, which means it affects under a certain population of patients in the United States. For that purpose sometimes it is advantageous to the review process, sometimes it will speed it up and helps us along.
and seek their approval to submit an application.
36:35 – And in my opinion, we should be successful in that. I think an application will be successful, that will be accepted by the FDA and the product will be approvable, for all of the reasons that Eyal outlined.”

So 76 refused chemo or radiotherapy… https://www.cvmresearch.com/p/cel-sci-investor-call-to-discuss

But the fact that we know multiple people refused surgery after multikine is promising.

When I asked specifically about secondary endpoints that’s what I was told… medical journal.

I believe they are leaving that for the Medical Journal.